Jan Skowronski, MD
Interventional Cardiology · Rockford, ILNPI 1790710283
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 89.0% of it on its own, with 19 other manufacturers making up the rest.
Across 153 payments — averaging $265.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$36K
- Silk Road Medical, Inc.$974
- Medtronic$502
- Reflow Medical Inc$464
- Endologix LLC$429
- Penumbra, Inc.$368
- plus $2K from 14 others
Across 78 payments — averaging $1409.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$92K
- Veryan Medical Incorporated$18K
What the payments were for
- Consulting fees$20,17550%
- Speaking & faculty fees$9,72024%
- Travel & lodging$4,47511%
- Food & beverage$6,31116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 58 | $36,201 |
| Silk Road Medical, Inc. | 6 | $974 |
| Medtronic(2 entities) | 36 | $502 |
| Reflow Medical Inc | 7 | $464 |
| Endologix LLC | 10 | $429 |
| Penumbra, Inc. | 4 | $368 |
| Inari Medical, Inc. | 6 | $315 |
| Celonova Biosciences, Inc. | 2 | $223 |
| Abbott | 3 | $211 |
| Venturemed Group, Inc. | 2 | $146 |
| Thrombolex, Inc. | 2 | $146 |
| Edwards Lifesciences | 1 | $126 |
| Shockwave Medical, Inc | 1 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $98 |
| Philips North America LLC | 2 | $91 |
| Vasorum USA Inc. | 1 | $89 |
| Stryker | 1 | $75 |
| Asahi Intecc USA, Inc. | 1 | $60 |
| Siemens Medical Solutions USA, Inc. | 2 | $34 |
| Novartis | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ranger$9,820
- GENERAL - THERAPIES$8,010
- GENERAL VASCULAR INTERVENTION$4,856
- ENROUTE Transcarotid Neuroprotection System$873
- ENROUTE Transcarotid Stent System$873
- ENHANCE Transcarotid Peripheral Access Kit$873
- ENROUTE 0.014 Guidewire$873
- GENERAL ATHERECTOMY$452
- GENERAL VASCULAR ACCESS$291
- Indigo System$268
- ELUVIA$219
- FlowTriever$123
- ClotTriever$123
- FLEX Scoring Catheter$121
- Bashir Endovascular Catheter$116
- JETI$108
- Vascular Lithotripsy$107
- OPTICROSS$100
How this compares
$40,681 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $147,355 |
| Repatha SureclickEvolocumab | 45 | $33,564 |
| EntrestoSacubitril/Valsartan | 19 | $19,686 |
| XareltoRivaroxaban | 19 | $14,440 |
| BrilintaTicagrelor | 16 | $11,339 |
| ClopidogrelClopidogrel Bisulfate | 308 | $3,583 |
| Metoprolol Succinate | 173 | $2,823 |
| Rosuvastatin Calcium | 102 | $2,664 |
| Atorvastatin Calcium | 178 | $2,652 |
| Amlodipine Besylate | 198 | $1,887 |
| Cilostazol | 51 | $1,591 |
| Ranolazine ErRanolazine | 27 | $1,442 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 33 | $1,436 |
| Carvedilol | 157 | $1,366 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 16 | $1,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $21 | $19,68619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Rockford
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.